Rosen Law Firm reminds ADMA Biologics investors of the August 10 deadline to serve as lead plaintiff in a securities fraud class action
Executive summary: Rosen Law Firm reminded investors that those who bought ADMA Biologics shares between August 9, 2024 and March 25, 2026 and incurred losses exceeding $100,000 can apply to be lead plaintiff by August 10, 2026. Being appointed lead plaintiff can shape litigation strategy, affect potential settlement amounts, and influence ADMA Biologics’ legal costs and market perception.
Who is involved: Rosen Law Firm, ADMA Biologics Inc., eligible shareholders, and the federal court overseeing the class action.
Likely next: Investors must submit lead‑plaintiff applications by August 10, 2026; the court will then select a lead plaintiff, after which the case proceeds to discovery or settlement discussions.
Rosen Law Firm issued a press release on August 1, 2026 notifying purchasers of ADMA Biologics (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026 who suffered losses over $100,000 that they may apply to be lead plaintiff in a filed class‑action securities fraud lawsuit. The reminder cites the August 10, 2026 application deadline and outlines the alleged misrepresentations concerning the company's financial condition and revenue. No new factual developments beyond the reminder are reported.
Timeline
- — ADMA Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
Analysis — what this means
Likely next events
- August 10, 2026: Deadline for lead plaintiff applications in the ADMA Biologics securities fraud class action.
- Following selection, the discovery phase is expected to begin in Q4 2026.
Sectors affected
- Biologics
- Pharmaceuticals
Regulatory implications
- Potential enforcement of Securities Exchange Act §10(b) and Rule 10b-5 by the SEC if the alleged misrepresentations are proven.
Historical parallels
- In July 2026, Rosen Law Firm issued analogous lead‑plaintiff reminders for Wix.com and GeneDx Holdings securities fraud class actions.
Key entities
Sources
Related cases
- Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
- ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
- ADMA Biologics faces a looming August 10 deadline for investors to assume lead plaintiff role in a securities fraud class action, highlighting ongoing litigation risk for the biotech firm
- ADMA Biologics faces an August 10 deadline for lead plaintiff applications in a securities fraud class action
- ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks
- ADMA Biologics shareholders invited to lead securities fraud class action over alleged financial misrepresentations